Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...
Allina Health Minneapolis Heart Institute first in Minn., Upper Midwest to use new, FDA-approved device to treat persistent ...
Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...
Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...
Implementation of an electronic patient-recorded outcome (ePRO) monitoring system improves patient-physician communication in cardiovascular care.
Researchers have found that Factor XI inhibitors, such as abelacimab, reduce bleeding risks in atrial fibrillation patients more effectively than standard anticoagulants.
Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even ...
Recent research shows the incredible success of radiofrequency ablation in treating AFib, offering renewed hope for patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback